Rheumatoid Arthritis

Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.

Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.

The use of machine learning models to predict treatment response in rheumatoid arthritis is increasing, though approximately 80% show “unclear and high risk of bias,” according to data published in Seminars in Arthritis and Rheumatism.

Systemic immune-inflammation index levels may be used to predict all-cause and cardiovascular mortality among patients with rheumatoid arthritis, according to data published in Scientific Reports.

Former New York Yankees center fielder Bernie Williams is sharing resources for patients with interstitial lung disease as a tribute to his late father, who lost his battle with idiopathic pulmonary fibrosis in 2001.

Olokizumab combined with methotrexate for the treatment of rheumatoid arthritis maintains its safety and efficacy profile through 106 weeks, according to data published in Annals of the Rheumatic Diseases.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

In patients with rheumatoid arthritis who have an inadequate response to methotrexate, a treatment sequence beginning with a biosimilar appeared cost-effective compared with leflunomide, according to data published in JAMA Network Open.

Latin American patients with rheumatoid arthritis experience fewer serious adverse events, including major adverse cardiovascular events and malignancy, than patients who are not Latin American, according to a study.